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Transforming growth factor (TGF)-
 
 
 
1 is a major pluripotential cytokine with a pronounced 
immunosuppressive effect and its deficiency results in lethal autoimmunity in mice. 
However, mechanisms of its immunosuppressive action are not completely understood. Here, 
we report that TGF-
 
 
 
1 supports the maintenance of Foxp3 expression, regulatory function, 
and homeostasis in peripheral CD4
 
 
 
CD25
 
 
 
 regulatory T (T reg) cells, but is not required for 
their thymic development. We found that in 8–10-d-old TGF-
 
 
 
1–deficient mice, peripheral, 
but not thymic, T reg cells are significantly reduced in numbers. Moreover, our experiments 
suggest that a defect in TGF-
 
 
 
–mediated signaling in T reg cells is associated with a decrease 
in Foxp3 expression and suppressor activity. Thus, our results establish an essential link 
between TGF-
 
 
 
1 signaling in peripheral T reg cells and T reg cell maintenance in vivo.
 
CD4
 
 
 
CD25
 
 
 
 regulatory T (T reg) cells play a
major role in the maintenance of immune toler-
ance to self and in the control of autoimmunity
(1, 2). T reg cells have been shown to inhibit
autoimmunity in a number of experimental
models, including diabetes and inflammatory
bowel disease in rodents (3, 4). They are also
involved in regulating T cell homeostasis (1, 5).
Additional studies have demonstrated their role
in organ transplant tolerance and in modulation
of immune responses to pathogens (6, 7). This
CD4
 
 
 
 T cell subset constitutes 
 
 
 
5–10% of pe-
ripheral CD4
 
 
 
 T cells and is capable of inhib-
iting the responses of CD4
 
 
 
CD25
 
 
 
 and CD8
T cells in vitro and in vivo (1).
Recently, Foxp3, a member of the fork-
head winged helix protein family of transcrip-
tion factors, has been identified as a specific
molecular marker for T reg cells and its ex-
pression is essential for programming T reg cell
development and function (8–11). The Foxp3
gene is highly conserved, and the function of
Foxp3 appears to be similar in both humans
and mice, as Foxp3 mutations result in a fatal
autoimmune pathologies affecting multiple or-
gans in both species (9, 10, 12, 13).
The phenotype of Foxp3 knockout mice
closely resembles that of animals deficient in
TGF-
 
 
 
 1 (
 
Tgf-
 
 
 
1
 
 
 
/
 
 
 
), with both mutants devel-
oping a lethal lymphoproliferative autoimmune
syndrome and succumbing to disease at 3–4
wk of age (10, 14). TGF-
 
 
 
1 is a widely dis-
tributed immunomodulatory cytokine. TGF-
 
 
 
1
signals through a heterodimeric receptor com-
plex formed by TGF-
 
 
 
RI and TGF-
 
 
 
RII
subunits. Binding of TGF-
 
 
 
1 to the receptor
complex activates the intracellular kinase do-
main, which leads to the phosphorylation and
activation of members of the Smad protein
family and subsequent regulation of TGF-
 
 
 
–
dependent gene expression (15).
An important role of TGF-
 
 
 
1 in down-
modulation of T cell–mediated immune re-
sponses and in controlling autoimmunity has
been clearly established (15). Mice deficient in
TGF-
 
 
 
RII receptor or expressing a dominant
negative form of TGF-
 
 
 
RII receptor (DN–
TGF-
 
 
 
RII) encoded by a transgene under a T
cell–specific promoter exhibit inflammatory infil-
tration in multiple organs and uncontrolled T cell
proliferation (16, 17) with features similar to that
of the 
 
Tgf-
 
 
 
1
 
 
 
/
 
 
 
 
 
mice. Notably, several recent
reports suggested that TGF-
 
 
 
1 produced by T
reg cells, and possibly decorating their plasma
membrane via binding to T reg cell TGF-
 
 
 
 re-
ceptors, may serve as an effector mechanism of
suppression (18, 19). However, a subsequent in
vitro study failed to reproduce this finding (20).
Therefore, we revisited the role that TGF-
 
 
 
1 plays in T reg cell biology by directly ex-
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amining potential effect of TGF-
 
 
 
1 deficiency on T reg
cells. This was achieved by analyzing the T reg cell subsets in
young 
 
Tgf
 
-
 
 
 
1
 
 
 
/
 
 
 
 mice. We have found that TGF-
 
 
 
1 pro-
duced by T reg cells is unlikely to play a role as a nonredun-
dant effector molecule mediating T reg cell suppressor func-
tion. However, Foxp3 expression, the size of peripheral T
reg cell compartment, and suppressive activity are dependent
on signals induced by TGF-
 
 
 
 in T reg cells.
 
RESULTS AND DISCUSSION
TGF-
 
 
 
1 is required for peripheral T reg cell homeostasis
 
Although a role of TGF-
 
 
 
–dependent signals has been well
documented in the control of T cell activation and inflam-
mation in vivo (16), a connection between TGF-
 
 
 
1 and T
reg cell function in vivo and in vitro has been controversial.
Two recent in vitro studies have shown no demonstrable
role for TGF-
 
 
 
1 produced by T reg cells in the suppressor
function (20, 21). However, another set of studies suggested
that TGF-
 
 
 
1 produced by T reg cells is an essential effector
molecule because, in these experiments, either anti–TGF-
 
 
 
1–neutralizing antibodies or a soluble form of TGF-
 
 
 
RII
abrogated T reg cell–mediated suppression in vitro and in
vivo (18, 19). To reexamine a role for TGF-
 
 
 
1 in T reg cell
development and function, we used mice deficient for 
 
Tgf-
 
 
 
1
 
 expression, which are known to develop an early onset
lethal lymphoproliferative autoimmune syndrome (14). To
avoid potential artifacts due to pathology observed in af-
fected 
 
Tgf-
 
 
 
1
 
–deficient mice, we examined the T cell com-
partment in 8–10-d-old 
 
Tgf-
 
 
 
1
 
 
 
/
 
 
 
 mice before the onset of
lymphoproliferation and clinical symptoms. In these young
mice, the analysis of thymus and spleen did not reveal any
difference in the proportion or absolute number of single
positive or double positive thymocytes, and the peripheral
CD4 and CD8 T cell compartments were similar in 
 
Tgf-
 
 
 
1
 
 
 
/
 
 
 
 mice and littermate controls (Fig. 1, a and b). In addi-
tion, peripheral 
 
Tgf-
 
 
 
1
 
 
 
/
 
 
 
 CD4 T cells expressed the same
level of the activation markers CD44 and CD62L as cells
from WT littermate controls (Fig. 1 c). However, in 12–14-
d-old mice, the number of peripheral CD4 T cells was in-
creased and some of these cells exhibited an activated pheno-
Figure 1. Decrease in peripheral CD4 CD25  T cells in Tgf- 1 /  
mice. Thymocytes (a) and splenocytes (b and c) from 8–10-d-old Tgf- 1 /  
mice or littermate controls were counted and stained for CD4 and CD8 and 
analyzed by flow cytometry. Peripheral CD4 T cells from Tgf- 1 /  mice 
(gray line) or littermate controls (black line) were stained for CD44 and 
CD62L. Thymocytes and splenocytes from 8–10-d-old Tgf- 1 /  mice or 
littermate controls were stained for CD4 and CD25 and analyzed by flow cy-
tometry (d). Proportion of CD4 CD25  cells among CD4 T cells (e, n   20). 
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type (i.e., increased CD44 and diminished CD62L expres-
sion as compared with T cells in WT littermate controls;
unpublished data). Thus, we have chosen to study the T reg
cell subset in 8–10-d-old 
 
Tgf
 
-
 
 
 
1
 
 
 
/
 
 
 
 mice. Flow cytometric
analysis revealed the peripheral CD4
 
 
 
CD25
 
 
 
 T cell com-
partment reduced by 2.5–3-fold in 
 
Tgf
 
-
 
 
 
1
 
 
 
/
 
 
 
 mice as com-
pared with the WT littermate controls (Fig. 1, d and e).
However, the CD4
 
 
 
CD25
 
 
 
 thymocyte subset in these ani-
mals was similar in size to that of littermate controls (Fig. 1,
d and e). Thus, these results indicate that TGF-
 
 
 
1 plays a
role in the peripheral T reg cell maintenance. In contrast
with these data, no difference was previously found in the
CD25
 
 
 
CD4
 
 
 
 T cell subsets not only in the thymus but also
in the periphery in 5–7-d-old TGF-
 
 
 
1–deficient mice (20).
This apparent discrepancy is most likely due to the fact that
the numbers of peripheral T reg cells in 5–7-d-old mice are
very small (unpublished data) and the vast majority of these
cells are recent arrivals from the thymus exhibiting normal
levels of Foxp3 characteristic of thymic T reg cells.
 
TGF-
 
 
 
1 is required to maintain Foxp3 expression in T reg cells
 
Next, we investigated whether TGF-
 
 
 
1 can regulate Foxp3
expression in T reg cells. First, we analyzed Foxp3 ex-
pression by intracellular staining of thymic and splenic
CD4
 
 CD25  T cells isolated from Tgf- 1 /  mice or WT
littermate controls (Fig. 2). No significant difference in
Foxp3 expression was observed in CD4 CD25  thymocytes
in mutant versus WT mice, whereas peripheral Tgf- 1 / 
CD4 CD25  T cells expressed significantly diminished level
of Foxp3 compared with the control. Thus, the absence of
TGF- 1 results in diminished Foxp3 expression in periph-
eral CD4 CD25  T cells in addition to a substantial de-
crease in size of this T cell compartment. Nevertheless, some
peripheral regulatory T cells in TGF- 1 null mice still main-
tain Foxp3 expression. The latter is likely due to normal
level of Foxp3 expression in thymocytes being preserved in
recent thymic emigrants. Provision of small amounts of
TGF- 1 by mother via breastfeeding and potential compen-
satory role of TGF- 2 and TGF- 3 can also contribute to
maintaining Foxp3 expression in some regulatory T cells in
the knockout mice. This result strongly suggests that TGF-
 1 is required for the maintenance of Foxp3 levels in pe-
ripheral T reg cells.
To test this hypothesis, CD4 CD25  T cells from either
8–10-d-old Tgf- 1 /  mice or littermate control mice were
adoptively transferred into lymphopenic TCR / -deficient
host treated with the neutralizing anti–TGF-  antibody or
isotype control IgG and analyzed 4 d later by flow cytome-
try (Fig. 3 a). As expected, the majority of Tgf- 1 / 
CD4 CD25  T cells transferred into anti–TGF- –treated
recipient mice continued to exhibit decreased Foxp3 levels,
whereas few Foxp3high cells were observed. The latter may
be due to incomplete antibody-mediated TGF- 1 deletion
in addition to the aforementioned compensatory role of
TGF- 2 and TGF- 3. However, transfer of these cells into
control IgG1-treated recipients, expressing normal amounts
of TGF- 1 (Fig. 3 b), led to an increase in Foxp3 expression
in T reg cells comparable to that of WT littermate control T
reg cells. Furthermore, transfer of CD4 CD25  T cells from
littermate control mice into recipients treated with the anti–
TGF-  antibody resulted in somewhat diminished Foxp3
expression in those cells after 4 d. Altogether, these results,
involving both genetic modifications and in vivo adoptive
transfer approaches, show that TGF- 1 maintains Foxp3 ex-
pression in peripheral T reg cells. Furthermore, the engage-
ment of TGF-  signaling pathway in T reg cells cultured in
the presence of TGF- 1 resulted in induction of Smad2
phosphorylation and concomitant increase in Foxp3 expres-
sion (Fig. 3 c). This observation further confirms that TGF- 
maintains Foxp3 high expression in T reg cells. By inference
from recent observations of acquisition of T reg cell pheno-
type and suppressor activity by CD4 CD25  T cells upon
retroviral transduction with Foxp3 (9, 10), the loss of pe-
ripheral T reg cells and their diminished suppressor activity
in Tgf- 1 /  mice can be a direct consequence of decreasing
levels of Foxp3.
TGF- 1 is required to maintain T reg cell suppressive function
After establishing a decreased level of Foxp3 expression in
T reg cells in the absence of TGF- 1, we investigated
whether TGF- 1 is also involved in the maintenance of
their regulatory function. Purified T reg cells from Tgf- 1 / 
mice or littermate control mice were cocultured with re-
sponder CD4 CD25  T cells from control mice in the
presence of Con A and T cell–depleted splenic APCs iso-
lated from either Tgf- 1 /  or littermate control mice (Fig.
Figure 2. Decrease in Foxp3 level in Tgf- 1 /  CD4 CD25  T cells. 
Thymocytes and splenocytes from 8–10-d-old Tgf- 1 /  mice or littermate 
controls were stained for CD4 and CD25 followed by anti-Foxp3 intracellular 
staining and analyzed by flow cytometry. Foxp3 staining in CD4 CD25  T 
cells (black line) and in CD4 CD25  (gray line) are shown. Isotype control 
staining is shown (dashed line). These results are representative of three 
different experiments.ROLE OF TGF- 1 IN T REG CELL MAINTENANCE | Marie et al. 1064
4 a). All combinations of WT and mutant T cells and APCs
resulted in a comparable suppression except for a signifi-
cantly diminished suppression by Tgf- 1 /  T reg cells ob-
served only in the presence of Tgf- 1 /  APCs. Thus, these
data demonstrate that TGF- 1 production by T reg cells is
dispensable for their suppressor function because APCs can
produce sufficient amounts of TGF- 1 to support T reg
cell–mediated suppression.
Although relative contribution of TGF- 1 produced by
T reg cells versus other cellular sources to T reg cell function
in vivo remains to be studied further, our results suggest a
requirement for paracrine TGF- 1 to maintain T reg cell
function in the periphery. This observation is in agreement
with recent experiments by Powrie et al., who showed that
an adoptive transfer of T reg cells isolated from TGF- 1–
deficient DO11.10 TCR transgenic mice can prevent colitis
mediated by WT CD4 CD25  T cells transferred into
SCID recipient mice. However, this suppression was abro-
gated in the presence of neutralizing antibodies specific for
TGF- 1 leading to disease progression (22). We also ob-
served that T reg cells from Tgf- 1 /  mice were able to
suppress autoimmunity developing in Tgf- 1 /  RAG / 
mice upon transfer of Tgf- 1 /  CD4 CD25  T cells (23).
These findings are consistent with our notion that Tgf- 1 / 
T reg cells require TGF- 1 provided by other cells to pre-
serve their functionality. Although the types of accessory
cells supplying TGF- 1 for T reg cells in vivo remains to be
determined, our analysis of in vitro TGF- 1 production us-
ing ELISA implicated APCs, such as dendritic cells, as the
likely candidates (unpublished data).
TGF- 1–mediated signaling in T reg cells is required to 
maintain suppressor function
However, these results do not address the question as to
whether T reg cells require TGF- 1 signaling to maintain
their functionality or whether T reg cells are “armed” with
the receptor-bound TGF- 1 produced either endogenously
or secreted by APCs. The latter possibility was raised by two
reports suggesting that receptor-bound TGF- 1 displayed
on the surface of T reg cells may function as an effector mol-
ecule in T reg cell–mediated suppression as assessed in an in
vitro assay (19, 24). To address these two possibilities, we
transduced T reg cells isolated from B6 mice with the Mig-
R2 retroviral vector encoding a dominant negative form of
the TGF- 1 receptor (DN–TGF- RII) and IRES-driven
tail-less human CD2 as a reporter. DN–TGF- RII was gen-
erated upon deletion of the TGF- RII kinase domain. As a
control, T reg cells were transduced with the MIG-R2 vec-
tor without insert. Transduced T reg cells were purified by
magnetic bead sorting using anti–human CD2 antibody.
Suppressor activity of DN–TGF- RII– and empty vector–
transduced T reg cells was tested in an in vitro suppression
assay. The regulatory capacity of T reg cells expressing DN–
TGF- RII was diminished, but not completely abolished, as
compared with the control T reg cells (Fig. 4 b). This is
likely due to the fact that T reg cells expressing DN–TGF-
 RII remain still sensitive to TGF- , albeit require an  10-
fold higher dose to induce Smad2 phosphorylation at a level
comparable to that of control MigR2-transduced cells (un-
published data). Importantly, although expression of DN–
TGF- RII inhibits TGF- –mediated signaling, it is ex-
pected to increase ability of T reg cells to capture TGF-  on
the plasma membrane. The analysis of suppressor function of
T reg cells transduced with DN–TGF -RII suggests that
impairment in suppressor function in the absence of TGF-
 1 is due to a signaling defect and not due to lack of recep-
tor-mediated display of TGF-  on the T reg cell surface.
Therefore, our results are consistent with the role of TGF- 
not as an effector molecule of suppression, but as a mediator
of signaling in T reg cells required to maintain their suppres-
sor function. Thus, our findings provide novel important in-
Figure 3. TGF- 1 is required to maintain Foxp3 in CD4 CD25  
T cells. T reg cells purified from spleen of 8–10-d-old Tgf- 1 /  mice or 
littermate controls were transferred into TCR / -deficient mice injected 
every other day with anti–TGF- 1 antibody or isotype control IgG. 4 d 
after transfer, cells from spleen and lymph nodes were stained for CD4 
and CD25 followed by anti-Foxp3 intracellular staining and analyzed by 
flow cytometry (a). Results are representative of three different experiments. 
Serum TGF- 1 in treated animals was measured by ELISA (b). Western blot 
analysis of Smad2 phosphorylation and Foxp3 expression in purified wild-
type T reg cells either freshly isolated or cultured for 24 h in the presence 
or absence of 100 pg/ml TGF- 1 (c).JEM VOL. 201, April 4, 2005 1065
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sights into the role of TGF- 1 in T reg cell function recon-
ciling previous contradictory observations.
Recently, several in vitro studies have reported acquisi-
tion of suppressor activity and Foxp3 expression in the bulk
populations of cultured murine and human CD4 CD25  T
cells upon activation in the presence of nanomolar amounts
of recombinant TGF- 1 (25, 26). Although these studies
opened up an important avenue for pharmacologic in vitro
manipulation of T cell function for potential therapeutic
purposes, there is no experimental evidence so far that such
high concentrations of TGF- 1 are ever attainable in vivo
and that such a conversion of CD4 CD25  into CD4 
CD25  T cells expressing Foxp3 can occur under physio-
logic conditions or in the course of immune inflammation.
In our earlier experiments, we failed to detect any measur-
able conversion of CD4 CD25  T cells into CD4 CD25 
upon their transfer into newborn Foxp3-deficient mice (10).
Ramsdell et al. have recently reported high levels of TGF-  1
Figure 4. TGF-  signaling is required to maintain regulatory func-
tion T reg cells. (a) Analysis of suppressor activity of T reg cells isolated 
from Tgf- 1 /  (gray symbols) or WT littermates (Lit, black symbols) in 
cocultures with freshly isolated B6 CD4 CD25  responder T cells in the 
presence of either Tgf- 1 /  or littermate control APCs and Con A. Prolif-
eration of CD4 CD25  T cells was determined after 72 h of culture by 
[3H]thymidine incorporation. Proliferation of CD4 CD25  from either 
control or Tgf- 1 /  mice in response to Con A was  300–500 cpm. The 
results are shown as mean cpm of [3H]thymidine incorporation in tripli-
cate cultures   SD. (b) T reg cells transduced with DN–TGF- RII–MigR2 
(MigR2 DN) or empty vector control (MigR2 Ev) were purified and cocul-
tured with freshly isolated B6 CD4 CD25  responder T cells in the presence 
of irradiated T cell–depleted splenic APCs and Con A. Proliferation was 
measured as described before. Results are representative of two or three 
different experiments.ROLE OF TGF- 1 IN T REG CELL MAINTENANCE | Marie et al. 1066
in Foxp3 mutant mice in addition to highly elevated levels
of a number of other cytokines (11). Nevertheless, it will
be of interest to experimentally test whether substantial
amounts of TGF- 1 displayed by some immunoprivileged
tissues and organs, like the ocular chamber of the eye, can fa-
cilitate maintenance, expansion, or de novo generation of
antigen-specific T reg cells (27). This idea is supported by
the recent observation of significant expansion and/or gen-
eration of protective T reg cells in pancreatic lymph nodes
and islets in NOD mice upon temporal TGF- 1 induction
in the  -cells (28).
In conclusion, our study demonstrates an essential in
vivo role for the TGF- 1–mediated signaling in the mainte-
nance of naturally arising regulatory CD4 CD25  T cell
numbers and function, and in the maintenance of Foxp3 ex-
pression in these cells in the periphery. These results demon-
strate an important role of TGF- 1 in T reg cell biology and
suggest additional applications for targeting of TGF- 1 sig-
naling pathway for therapeutic immunomodulation.
MATERIALS AND METHODS
Mice.  C57BL/6 (B6) and TCR / -deficient mice were purchased from
Charles River Breeding Laboratories and The Jackson Laboratory, respec-
tively. Tgf- 1 /  mice were previously described (29). All mice were main-
tained in a specific pathogen-free animal facility at the University of Wash-
ington and National Institutes of Health and handled in accordance with
the institutional guidelines.
Antibodies. Anti-Foxp3 IgG was purified on a protein G–Sepharose 4
Fast Flow column from the rabbit antiserum raised against purified His-
tagged recombinant Foxp3 protein. Biotinylated (bio), FITC-, PE-, cy-
chrome (CyC)-, peridinin chlorophyl protein (PerCP)-, and allophycocya-
nin-conjugated monoclonal antibodies to CD4 (L3T4), CD8  (53–6.7),
CD25 (7D4), CD25 (PC-61), CD62L (MEL-14), CD69 (H1.2F3), and
CD44 (IM7) were purchased from BD Biosciences and eBioscience. For
Western blotting, rabbit anti-Smad2, anti–Smad2-P (Chemicon), and anti-
Foxp3 antibodies were used in combination the donkey anti–rabbit
IgG–horseradish peroxidase secondary antibody (Amersham Biosciences).
Intracellular staining for Foxp3 was performed upon cell fixation and per-
meabilization with rabbit anti-Foxp3 IgG followed by biotinylated–goat
anti–rabbit IgG antibody (Jackson ImmunoResearch Laboratories) and strepta-
vidin-allophycocyanin (BD Biosciences; unpublished data).
TGF-  depletion. Mouse monoclonal anti–TGF- 1 (2G7; IgG1) anti-
body (30) and mouse IgG1 (Sigma-Aldrich) used as isotype control were
injected intraperitoneally (150  g/injection/animal) every other day, 4 d
before and after adoptive cell transfer. TGF- 1–specific ELISA kit (Quan-
tikine; R&D Systems) was used to measure TGF- 1 according to the man-
ufacturer’s protocol.
Cell purification.  Cell populations were purified using an AutoMACS
magnetic cell sorter and magnetic beads (Miltenyi Biotec) as described (10)
and/or using a FACSVantage cell sorter (BD Biosciences). Routinely, pu-
rity of all cell preparations was  90%. Flow cytometric analysis was per-
formed using a FACSCalibur flow cytometer.
Cell culture and in vitro suppression assay.  Cells were cultured in
RPMI 1640 supplemented with 10% FCS, 200 mM L-glutamine, 1 mM so-
dium pyruvate, 10 mM Hepes, 100 U/ml penicillin/streptomycin, and 5  
10 5 M 2-mercaptoethanol (RP-10).
Purified T reg cells were cultured for 24 h in the presence or absence of
100 pg/ml of TGF- 1 (R&D Systems). Western blot analysis was per-
formed after cell lysate separation in 12% SDS-PAGE gels (3   106 cell
equivalents/lane) as described elsewhere (10).
Suppression assays were performed as described (10). In brief, CD4 
CD25  T cells (4   104 cells/well) were stimulated for 72 h with 1  g/ml
of Con A in the presence of irradiated (2,000 rad) T cell–depleted spleno-
cytes (APCs) (2   105/well) in 96-well round-bottom plates, with indi-
cated numbers of CD4 CD25  T cells and pulsed with 1  Ci/well of
[3H]thymidine for the final 16 h of culture. Data are shown as mean
[3H]thymidine incorporation in triplicate cultures.
Retroviral infection.  The first 656 bp of the coding sequence of TGF-
 RII were subcloned from pcDNA3.1-myc-HisB DN-TGF- RII ( ) into
MSCV MigR2 retroviral vector. The vector DNA with or without insert
was transfected into the  NX-E packaging cell line using Fugene 6 reagent
(Roche) according to the manufacturer’s protocol. Retrovirus-containing
supernatant was collected after a 36-h culture of the transfected packaging
cells at 32 C. Freshly isolated MACS-purified CD4 CD25  T cells were
activated using plate-bound anti-TCR  chain and anti-CD28 antibodies,
in the presence of 100 U/ml recombinant human IL-2 (Hoffmann–La
Roche). After 24 h of activation, CD4 CD25  T cells were infected by re-
suspending cells in retrovirus-containing supernatants supplemented with 8
 g/ml polybrene and 50 U/ml of recombinant IL-2, followed by centrifu-
gation for 90 min at 2,500 revolutions/min. Cells were cultured for 48 h at
37 C in the presence of 200 U/ml IL-2 and 10 pg/ml TGF- 1 to maintain
CD25 and Foxp3 expression.
We thank the members of the Rudensky laboratory for discussions and for reading 
the text.
This work was supported by grants from International Human Frontier Science 
Program (to J.C. Marie) and National Institutes of Health nos. AI34206 and AI061816 
(to A.Y. Rudensky). A.Y. Rudensky is a Howard Hughes Medical Institute investigator.
The authors have no conflicting financial interests.
Submitted: 5 November 2004
Accepted: 15 February 2005
REFERENCES
1. Sakaguchi, S., N. Sakaguchi, J. Shimizu, S. Yamazaki, T. Sakihama, M.
Itoh, Y. Kuniyasu, T. Nomura, M. Toda, and T. Takahashi. 2001. Im-
munologic tolerance maintained by CD25  CD4  regulatory T cells:
their common role in controlling autoimmunity, tumor immunity, and
transplantation tolerance. Immunol. Rev. 182:18–32.
2. Shevach, E.M. 2002. CD4  CD25  suppressor T cells: more ques-
tions than answers. Nat. Rev. Immunol. 2:389–400.
3. Salomon, B., D.J. Lenschow, L. Rhee, N. Ashourian, B. Singh, A.
Sharpe, and J.A. Bluestone. 2000. B7/CD28 costimulation is essential
for the homeostasis of the CD4 CD25  immunoregulatory T cells
that control autoimmune diabetes. Immunity. 12:431–440.
4. Stephens, L.A., and D. Mason. 2000. CD25 is a marker for CD4 
thymocytes that prevent autoimmune diabetes in rats, but peripheral T
cells with this function are found in both CD25  and CD25  sub-
populations. J. Immunol. 165:3105–3110.
5. Annacker, O., R. Pimenta-Araujo, O. Burlen-Defranoux, and A. Ban-
deira. 2001. On the ontogeny and physiology of regulatory T cells. Im-
munol. Rev. 182:5–17.
6. Taylor, P.A., R.J. Noelle, and B.R. Blazar. 2001. CD4 CD25  im-
mune regulatory cells are required for induction of tolerance to alloan-
tigen via costimulatory blockade. J. Exp. Med. 193:1311–1318.
7. Belkaid, Y., C.A. Piccirillo, S. Mendez, E.M. Shevach, and D.L. Sacks.
2002. CD4 CD25  regulatory T cells control Leishmania major per-
sistence and immunity. Nature. 420:502–507.
8. Brunkow, M.E., E.W. Jeffery, K.A. Hjerrild, B. Paeper, L.B. Clark,
S.A. Yasayko, J.E. Wilkinson, D. Galas, S.F. Ziegler, and F. Ramsdell.
2001. Disruption of a new forkhead/winged-helix protein, scurfin, re-
sults in the fatal lymphoproliferative disorder of the scurfy mouse. Nat.
Genet. 27:68–73.
9. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatoryJEM VOL. 201, April 4, 2005 1067
BRIEF DEFINITIVE REPORT
T cell development by the transcription factor Foxp3. Science. 299:
1057–1061.
10. Fontenot, J.D., M.A. Gavin, and A.Y. Rudensky. 2003. Foxp3 pro-
grams the development and function of CD4 CD25  regulatory T
cells. Nat. Immunol. 4:330–336.
11. Khattri, R., T. Cox, S.A. Yasayko, and F. Ramsdell. 2003. An essen-
tial role for Scurfin in CD4 CD25  T regulatory cells. Nat. Immunol.
4:337–342.
12. Bennett, C.L., J. Christie, F. Ramsdell, M.E. Brunkow, P.J. Ferguson,
L. Whitesell, T.E. Kelly, F.T. Saulsbury, P.F. Chance, and H.D. Ochs.
2001. The immune dysregulation, polyendocrinopathy, enteropathy,
X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat.
Genet. 27:20–21.
13. Wildin, R.S., F. Ramsdell, J. Peake, F. Faravelli, J.L. Casanova, N. Buist,
E. Levy-Lahad, M. Mazzella, O. Goulet, L. Perroni, et al. 2001. X-linked
neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is
the human equivalent of mouse scurfy. Nat. Genet. 27:18–20.
14. Shull, M.M., I. Ormsby, A.B. Kier, S. Pawlowski, R.J. Diebold, M.
Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin, et al. 1992. Tar-
geted disruption of the mouse transforming growth factor-beta 1 gene
results in multifocal inflammatory disease. Nature. 359:693–699.
15. Letterio, J.J., and A.B. Roberts. 1998. Regulation of immune re-
sponses by TGF-beta. Annu. Rev. Immunol. 16:137–161.
16. Gorelik, L., and R.A. Flavell. 2000. Abrogation of TGFbeta signaling
in T cells leads to spontaneous T cell differentiation and autoimmune
disease. Immunity. 12:171–181.
17. Leveen, P., J. Larsson, M. Ehinger, C.M. Cilio, M. Sundler, L.J. Sjo-
strand, R. Holmdahl, and S. Karlsson. 2002. Induced disruption of the
transforming growth factor beta type II receptor gene in mice causes a
lethal inflammatory disorder that is transplantable. Blood. 100:560–568.
18. Zhang, X., L. Izikson, L. Liu, and H.L. Weiner. 2001. Activation of
CD25( )CD4( ) regulatory T cells by oral antigen administration. J.
Immunol. 167:4245–4253.
19. Nakamura, K., A. Kitani, and W. Strober. 2001. Cell contact-depen-
dent immunosuppression by CD4 CD25  regulatory T cells is medi-
ated by cell surface-bound transforming growth factor  . J. Exp. Med.
194:629–644.
20. Piccirillo, C.A., J.J. Letterio, A.M. Thornton, R.S. McHugh, M. Ma-
mura, H. Mizuhara, and E.M. Shevach. 2002. CD4 CD25  regula-
tory T cells can mediate suppressor function in the absence of trans-
forming growth factor  1 production and responsiveness. J. Exp. Med.
196:237–246.
21. Takahashi, T., Y. Kuniyasu, M. Toda, N. Sakaguchi, M. Itoh, M.
Iwata, J. Shimizu, and S. Sakaguchi. 1998. Immunologic self-tolerance
maintained by CD25 CD4  naturally anergic and suppressive T cells:
induction of autoimmune disease by breaking their anergic/suppressive
state. Int. Immunol. 10:1969–1980.
22. Fahlen, L., S. Read, L. Gorelik, S.D. Hurst, R.I. Coffman, R.A. Fla-
vell, and F. Powrie. 2005. T cells that cannot respond to TGF-  escape
control by CD4 CD25  regulatory T cells. J. Exp. Med. 201:737–746.
23. Mamura, M., W. Lee, T.J. Sullivan, A. Felici, A.L. Sowers, J.P. Alli-
son, and J.J. Letterio. 2004. CD28 disruption exacerbates inflamma-
tion in Tgf-{beta}1 /  mice: in vivo suppression by CD4 
CD25  regulatory T cells independent of autocrine TGF-beta1.
Blood. 103:4594–4601.
24. Annunziato, F., L. Cosmi, F. Liotta, E. Lazzeri, R. Manetti, V. Va-
nini, P. Romagnani, E. Maggi, and S. Romagnani. 2002. Phenotype,
localization, and mechanism of suppression of CD4 CD25  human
thymocytes. J. Exp. Med. 196:379–387.
25. Chen, W., W. Jin, N. Hardegen, K.J. Lei, L. Li, N. Marinos, G.
McGrady, and S.M. Wahl. 2003. Conversion of peripheral CD4 
CD25  naive T cells to CD4 CD25  regulatory T cells by TGF-  in-
duction of transcription factor Foxp3. J. Exp. Med. 198:1875–1886.
26. Zheng, S.G., J.H. Wang, J.D. Gray, H. Soucier, and D.A. Horwitz.
2004. Natural and induced CD4 CD25  cells educate CD4 
CD25  cells to develop suppressive activity: the role of IL-2, TGF-
beta, and IL-10. J. Immunol. 172:5213–5221.
27. Stein-Streilein, J., and J.W. Streilein. 2002. Anterior chamber associ-
ated immune deviation (ACAID): regulation, biological relevance, and
implications for therapy. Int. Rev. Immunol. 21:123–152.
28. Peng, Y., Y. Laouar, M.O. Li, E.A. Green, and R.A. Flavell. 2004.
TGF-{beta} regulates in vivo expansion of Foxp3-expressing CD4 
CD25  regulatory T cells responsible for protection against diabetes.
Proc. Natl. Acad. Sci. USA. 101:4572-4577.
29. Kulkarni, A.B., C.G. Huh, D. Becker, A. Geiser, M. Lyght, K.C.
Flanders, A.B. Roberts, M.B. Sporn, J.M. Ward, and S. Karlsson.
1993. Transforming growth factor beta 1 null mutation in mice causes
excessive inflammatory response and early death. Proc. Natl. Acad. Sci.
USA. 90:770–774.
30. Lucas, C., L.N. Bald, B.M. Fendly, M. Mora-Worms, I.S. Figari, E.J.
Patzer, and M.A. Palladino. 1990. The autocrine production of trans-
forming growth factor-beta 1 during lymphocyte activation. A study
with a monoclonal antibody-based ELISA. J. Immunol. 145:1415–1422.